Search research articles
Contact Us
Filters
Showing results (11-20 of 51) with videos related to
Page
of 6
Sort By:
Patient Preference and Adherence
|
November 26, 2009
Can adherence to antihypertensive therapy be used to promote adherence to statin therapy?
Richard H Chapman, Elise M Pelletier, Paula J Smith, et al.
Journal of Managed Care & Specialty Pharmacy
|
June 5, 2023
Real-world treatment modalities, health care resource utilization, and costs among commercially insured patients with newly diagnosed major depressive disorder in the United States
Lia N Pizzicato, Richard Z Xie, Yiling Yang, et al.
Cardiovascular Diabetology
|
September 29, 2009
Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting
Robert J Straka, Larry Z Liu, Prafulla S Girase, et al.
Journal of Medical Economics
|
April 27, 2012
Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis
Elise M Pelletier, Manjiri Pawaskar, Paula J Smith, et al.
Cost Effectiveness and Resource Allocation : C/E
|
October 12, 2020
Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
Praveen Thokala, Matt Stevenson, Varun M Kumar, et al.
Annals of Internal Medicine
|
April 19, 2017
Cost-Effectiveness of Sacubitril-Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction
Alexander T Sandhu, Daniel A Ollendorf, Richard H Chapman, et al.
Annals of Internal Medicine
|
August 30, 2016
Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction
Alexander T Sandhu, Daniel A Ollendorf, Richard H Chapman, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
October 2, 2009
Are high-risk hypertensive patients being prescribed concomitant statin therapy?: a retrospective cohort study
Richard H Chapman, Allison A Petrilla, Lance Berman, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 16, 2019
Current Value Frameworks-What's New?
Richard J Willke, Richard H Chapman, Joshua J Seidman, et al.
Health Economics
|
May 6, 2004
When does quality-adjusting life-years matter in cost-effectiveness analysis?
Richard H Chapman, Marc Berger, Milton C Weinstein, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 51) with videos related to
Sort By:
Page
of 6
Patient Preference and Adherence
|
November 26, 2009
Can adherence to antihypertensive therapy be used to promote adherence to statin therapy?
Richard H Chapman, Elise M Pelletier, Paula J Smith, et al.
Journal of Managed Care & Specialty Pharmacy
|
June 5, 2023
Real-world treatment modalities, health care resource utilization, and costs among commercially insured patients with newly diagnosed major depressive disorder in the United States
Lia N Pizzicato, Richard Z Xie, Yiling Yang, et al.
Cardiovascular Diabetology
|
September 29, 2009
Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting
Robert J Straka, Larry Z Liu, Prafulla S Girase, et al.
Journal of Medical Economics
|
April 27, 2012
Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis
Elise M Pelletier, Manjiri Pawaskar, Paula J Smith, et al.
Cost Effectiveness and Resource Allocation : C/E
|
October 12, 2020
Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
Praveen Thokala, Matt Stevenson, Varun M Kumar, et al.
Annals of Internal Medicine
|
April 19, 2017
Cost-Effectiveness of Sacubitril-Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction
Alexander T Sandhu, Daniel A Ollendorf, Richard H Chapman, et al.
Annals of Internal Medicine
|
August 30, 2016
Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction
Alexander T Sandhu, Daniel A Ollendorf, Richard H Chapman, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
October 2, 2009
Are high-risk hypertensive patients being prescribed concomitant statin therapy?: a retrospective cohort study
Richard H Chapman, Allison A Petrilla, Lance Berman, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 16, 2019
Current Value Frameworks-What's New?
Richard J Willke, Richard H Chapman, Joshua J Seidman, et al.
Health Economics
|
May 6, 2004
When does quality-adjusting life-years matter in cost-effectiveness analysis?
Richard H Chapman, Marc Berger, Milton C Weinstein, et al.
Page
of 6